Quick Answer
Prime Medicine, Inc. reported Stockholders Equity of $120.87 million for the year ending 2025.
- Prime Medicine, Inc. showed a decrease of -21.1% in Stockholders Equity from 2024 to 2025.
- This data is from Prime Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$85.31 million | Q2 2021: -$78.37 million | Q3 2021: -$94.42 million | Q1 2022: -$166.94 million | Q2 2022: -$195.06 million | Q3 2022: -$223.10 million | Q1 2023: $278.80 million | Q2 2023: $240.10 million | Q3 2023: $193.96 million | Q1 2024: $243.77 million | Q2 2024: $196.59 million | Q3 2024: $189.50 million | Q1 2025: $106.92 million | Q2 2025: $60.86 million | Q3 2025: $161.82 million.
- Over the full 7 years of available data (2019 to 2025), Prime Medicine, Inc.'s Stockholders Equity has grown by 4,752.3%.
- Historical annual values: Fiscal year 2025: $120.87 million | Fiscal year 2024: $153.15 million | Fiscal year 2023: $133.07 million | Fiscal year 2022: $316.27 million | Fiscal year 2021: -$156.24 million | Fiscal year 2020: $2.34 million | Fiscal year 2019: -$2.60 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: